Clinical observation on the effects of the treatment of low-dose hydrochlorothiazide combining with irbesartan on essential hypertension

doi:10.3969/j.issn.1006-7795.2018.01.026

Abstract

Abstract: Objective To observe the efficacy of low-dose hydrochlorothiazide combining with irbesartan on essential hypertension(EH), and to investigate its effects on fasting plasma glucose(FPG), blood liquid, electrolyte and uric acid(UA).Methods A total of 94 EH patients were randomly divided into control group (n=47) and study group (n=47). Control group was treated with irbesartan, while study group was treated with low-dose hydrochlorothiazide combining irbesartan. Curative effects of blood pressure and parameters of FPG, total cholesterol (TC), triglyceride (TG), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), Na⁺, Cl^-, K⁺ and UA were analyzed and compared between the two groups before and after 2 months of treatment.Results Compared with before treatment, blood pressure of two group were significantly decreased after treatment (P<0.05), and after treatment the systolic blood pressure and diastolic blood pressure of study group were (132.15±12.30)mmHg (1 mmHg=0.133 kPa) and (82.89±7.26)mmHg, and the systolic and diastolic blood pressure of control group were (139.85±13.89)mmHg and (88.02±8.77)mmHg, but the decrease of blood pressure of study group was more significant (P<0.05). The total effective rate of study group was 95.74%, significantly higher than that of control group (78.72%), there was statistical significance (P<0.05). Before and after treatment, the levels of FPG, blood liquid, electrolyte and UA in two groups had no significant difference (P>0.05), and those in study group also had no significant difference before and after treatment (P>0.05).Conclusion Low-dose hydrochlorothiazide combining with irbesartan in the treatment of EH, can significantly improve the crutive effect, and has no significant influence on FPG, blood liquid, electrolyte and UA.

Key words: hydrochlorothiazide, irbesartan, essential hypertension

CLC Number:

R544.1

Lyu Man. Clinical observation on the effects of the treatment of low-dose hydrochlorothiazide combining with irbesartan on essential hypertension[J]. Journal of Capital Medical University, 2018, 39(1): 148-152.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2018.01.026

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2018/V39/I1/148

References

[1] 中国高血压防治指南修订委员会. 中国高血压防治指南2010年[J].中华心血管病杂志,2011,39(7):579-616.
[2] 中华心血管病杂志编委会心血管药物对策专题组.心血管药物临床试验评价方法的建议[J].中华心血管病杂志,1998,26(1):5-11.
[3] 吴江.抗高血压药物联合用药研究进展[J].中国药事,2012,26(1):80-83.
[4] 杨华.高血压患者联合用药的禁忌[J].中西医结合心血管病杂志,2017,5(12):23-26.
[5] 张万义,宋安洋,周明龙.不同联合用药对老年单纯收缩期高血压患者大动脉僵硬度的疗效比较[J].中华老年心脑血管病杂志,2016,18(8):829-832.
[6] 王磊,魏新伟,于芳.不同降压药物联合治疗对老年高血压患者血压变异性的影响[J].天津医药,2016,44(1):105-109.
[7] 张妮,刘蔚.门诊高血压患者联合用药的调查分析[J].中国临床医生杂志,2015,43(6):48-50.
[8] 黄小华.厄贝沙坦氢氯噻嗪复方片剂治疗原发性高血压的临床效果观察[J].当代医学,2015,21(16):122-123.
[9] 李伯庆.厄贝沙坦氢氯噻嗪和福辛普利治疗原发性高血压的疗效比较[J].成都医学院学报,2015,10(3):346-349.
[10] 宋海宁,赖海燕,李茜.依那普利或厄贝沙坦联合氢氯噻嗪治疗中重度高血压的临床疗效及安全性评价[J].中国临床药理学杂志,2015,31(16):1563-1565.
[11] 杨政杰,秦娴,全文超,等.奥美沙坦联合氢氯噻嗪对原发性高血压患者及左心室肥厚的影响[J].中国基层医药,2011,18(22):3033-3034.
[12] 张陶丽,张春晓.厄贝沙坦联合苯磺酸氨氯地平治疗老年糖尿病合并高血压伴高尿酸血症[J].中国临床医生,2011,39(12):25-27.
[13] 郭爱玲.氢氯噻嗪及氢氯噻嗪与依那普利合用对轻中度高血压病患者血脂及电解质的影响[J].中西医结合心脑血管病杂志,2010,8(7):860-861.
[14] Huang Q F, Sheng C S, Li Y, et al.Efficacy and safety of a fixed combination of irbesartan/hydrochlorothiazide in Chinese patients with moderate to severe hypertension[J].Drugs R D, 2013,13(2):109-107.
[15] Malacco E, Omboni S, Parati G. Blood pressure response to zofenopril or irbesartan each combined with hydrochlorothiazide in high-risk hypertensives uncontrolled by monotherapy:a randomized, double-blind, controlled, parallel group, noninferiority trial[J]. Int J Hypertens, 2015, 2015:139456.
[16] Agabiti-Rosei E, Manolis A, Zava D, et al. Zofenopril plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients[J]. Adv Ther, 2014,31(2):217-233.
[17] Al Balushi K A, Habib J Q, Al-Zakwani I. Comparative efficacy of irbesartan/hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure:a retrospective observational study in oman[J]. Med Princ Pract, 2013,22(3):265-269.